COMMUNIQUÉS West-GlobeNewswire

Abiomed annonce un chiffre d'affaires au T1 de l'exercice financier 2018 de 132,5 millions de dollars, en progression de 29 % par rapport à l'année précédente
28/07/2017
La société annonce le remboursement japonais pour les pompes cardiaques Impella® et augmente la fourchette inférieure de ses prévisions relatives au chiffre d'affaires pour l'exercice financier 2018 DANVERS, [...]
iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region
28/07/2017
iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region Funding will support the clinical development of the Company's lead innovative immuno-oncology drug Gosselies, Belgium - July 28, [...]
U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron
28/07/2017
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
DBV Technologies Résultats financiers du premier semestre 2017
28/07/2017
Communiqué de Presse Montrouge, France, le 28 juillet 2017 (7H30 CEST) DBV Technologies Résultats financiers du premier semestre 2017 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), société [...]
DBV Technologies Reports First Half 2017 Financial Results
28/07/2017
Press Release Montrouge, France, July 28, 2017 DBV Technologies Reports First Half 2017 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today reported first half 2017 [...]
ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
28/07/2017
Press release PDF This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Navamedic ASA: Second quarter results 2017
28/07/2017
Oslo, 28 July 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 89.7 million in the second quarter of 2017 (NOK 66.7 million in Q2 2016), representing a growth of 34.4%, following the successful ramp-up of the [...]
Essilor - Communiqué : Une performance résiliente au premier semestre
28/07/2017
Une performance résiliente au premier semestre Version PDF du communiqué Hausse de 9,1 % du chiffre d'affaires, dont 6,9 % hors change Meilleure dynamique en Amérique du Nord, bonne performance de l'Europe Pays à forte [...]
Essilor - News Release: Resilient First Half
28/07/2017
Resilient First Half PDF Version of the news release Revenue growth of 9.1% and 6.9% in constant currency Improving momentum in North America, good performance in Europe Fast-Growing Markets impacted by a decline in [...]
Essilor : Mise à disposition du rapport financier semestriel 2017
28/07/2017
Mise à disposition du rapport financier semestriel 2017 Charenton-le-Pont, France (le 28 juillet 2017 - 6h30) - Essilor International publie ce matin son rapport financier semestriel 2017. Ce document comprend les [...]
Essilor: Publication of the 2017 Interim Financial Report
28/07/2017
Publication of the 2017 Interim Financial Report Charenton-le-Pont, France (July 28, 2017 - 6:30 am) - The Essilor International 2017 Interim Financial Report is being published today. The report comprises the interim [...]
Solid financials support R&D progress
27/07/2017
Solid financials support R&D progress This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are [...]
Servier licenses GLPG1972 in osteoarthritis from Galapagos
27/07/2017
Servier licenses GLPG1972 in osteoarthritis This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are [...]
Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events
27/07/2017
Bagsværd, Denmark, 27 July 2017 - The European Commission has approved an update to the Victoza ® (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events [...]
GUERBET : Chiffre d'affaires au 30 juin 2017
27/07/2017
397,7 M€ à taux de change constant : +5,6% Progression satisfaisante de l'activité Villepinte, le 27 juillet 2017 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie [...]
GUERBET : Revenue at June 30, 2017
27/07/2017
€397.7 million at constant exchange rates, up 5.6% Satisfactory activity growth Villepinte, July 27, 2017 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is [...]
Diaxonhit : Chiffre d'Affaires du 1er semestre 2017 en croissance de 31% à 19,6 millions d'euros
27/07/2017
DIAXONHIT : chiffre d'affaires du 1er semestre 2017 en croissance de 31% Chiffre d'affaires semestriel consolidé en forte progression de +31% à 19,6 millions d'euros, en raison de l'acquisition d'Eurobio le 30 mars 2017 [...]
Oriola Corporation - Repurchase of own shares on 27 July 2017
27/07/2017
ORIOLA CORPORATION STOCK EXCHANGE RELEASE 27 JULY 2017 AT 18:45 EEST In the Nasdaq Helsinki Date 27 July 2017 Exchange transaction Buy Share trading code OKDBV Amount, shares 11 209 Average price/share, EUR 3,5995 Total [...]
Ossur Hf : Insider Trading
27/07/2017
Announcement Össur hf. No.53/2017 Reykjavík, 27 July 2017 Auðkenni útgefanda/Trade ticker: OSSR Nafn útgefanda/Issuer: Össur hf. Dagsetning tilkynningar/Date of announcement: 27 July 2017 Nafn fruminnherja/Name primary [...]

Pages